AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2958398
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) 10 mg sublingually
Trial: 2958398
Drug: Nifedipine 20
RxNorm normalized name: nifedipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 20 mg sublingually followed by Isosorbide dinitrate (ISDN) 10 mg
Trial: 15653117
Drug: Xuezhikang 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuezhikang 1200 mg/day
Trial: 15653117
Drug: Xuezhikang 2400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuezhikang 2400 mg/day
Trial: 10554570
Drug: Detection of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detection of ICA antibodies
Trial: 10554570
Drug: Detection of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detection of anti-GAD antibodies
Trial: 10554570
Drug: Detection of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detection of IA-2 antibodies
Trial: 10554570
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of 2 types of antibodies
Trial: 30712687
Drug: Part-time wear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part-time wear of Twin-block appliance (12 hours daily)
Trial: 30712687
Drug: Full-time wear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-time wear of Twin-block appliance (22 hours daily)
Trial: 28323044
Drug: Medium doses
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium doses of vitamin D (1600, 2400, 3200 IU)
Trial: 28323044
Drug: Low doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low doses of vitamin D (400, 800 IU)
Trial: 28323044
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of vitamin D (4000, 4800 IU)
Trial: 24820858
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg ginger, two times per day, 30 min before each dose of antiretroviral regimen for 14 days
Trial: 24820858
Drug: Placebo, two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, two times per day, 30 min before each dose of antiretroviral regimen for 14 days
Trial: 10580169
Drug: N-monomethyl-L-arginine (LNMMA)
RxNorm normalized name: .alpha.N-(methoxycarbonyl)-L-arginine
DrugBank: Tilarginine (DB11815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-monomethyl-L-arginine (LNMMA)
Trial: 8174950
Drug: Cisapride (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (10 mg twice daily)
Trial: 3515333
Drug: Oral naproxen
RxNorm normalized name: naproxen Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral naproxen (250 mg per day for two weeks)
Trial: 3515333
Drug: Local injection
RxNorm normalized name: Sclerosing agents for local injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local injection of betamethasone (6 mg in a long-acting form)
Trial: 2893916
Drug: digoxin 0.125
RxNorm normalized name: digoxin 0.125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: digoxin 0.125 mg twice daily
Trial: 26372401
Drug: D-cycloserine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-cycloserine (50 mg) administered after each of 10 CBT sessions
Trial: 26372401
Drug: Placebo (PBO)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PBO) administered after each of 10 CBT sessions
Trial: 26372401
Drug: D-cycloserine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-cycloserine (50 mg) with high homework compliance
Trial: 21397483
Drug: Formoterol (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol (12 μg, twice daily for 14 days)
Trial: 21397483
Drug: Tiotropium (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium (18 μg, once daily for 14 days)
Trial: 21397483
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of Formoterol (200 μg)
Trial: 21397483
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of Tiotropium
Trial: 21397483
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of Salbutamol (200 μg)
Trial: 10700672
Drug: PRED 40
RxNorm normalized name: A-MethaPred 40 MG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRED 40 mg in the morning
Trial: 9596864
Drug: 15‐methyl‐PGF2 alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15‐methyl‐PGF2 alpha 0.100 mg
Trial: 9596864
Drug: 15‐methyl‐PGF2 alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15‐methyl‐PGF2 alpha 0.125 mg
Trial: 9596864
Drug: 15‐methyl‐PGF2 alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15‐methyl‐PGF2 alpha 0.200 mg
Trial: 8404386
Drug: Transproctoscopic Doppler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transproctoscopic Doppler ultrasound followed by local injection treatment with 5 percent phenol almond oil
Trial: 2948853
Drug: RA27/3 rubella
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RA27/3 rubella vaccine from Institut Merieux
Trial: 2948853
Drug: RA27/3 rubella
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RA27/3 rubella vaccine from Wellcome
Trial: 26242331
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no Epo treatment)
Trial: 8412310
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion carboplatin 250 mg/m2 per day for 5 days and etoposide 150 mg/m2 per day for 5 days.
Trial: 8412310
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion carboplatin 310 mg/m2 per day for 5 days and etoposide 150 mg/m2 per day for 5 days.
Trial: 20683035
Drug: saracatinib 500
RxNorm normalized name: Saracatinib
DrugBank: Saracatinib (DB11805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saracatinib 500 mg
Trial: 20683035
Drug: saracatinib 125
RxNorm normalized name: Saracatinib
DrugBank: Saracatinib (DB11805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saracatinib 125 mg for 14 days
Trial: 12680790
Drug: WBRT (Whole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WBRT (Whole Brain Radiation Therapy) alone
Trial: 8904876
Drug: Anti-Tf receptor
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-Tf receptor antibody 42/6
Trial: 8904876
Drug: Blockade of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blockade of Tf-mediated iron uptake with anti-Tf receptor antibody 42/6
Trial: 1652265
Drug: pH-adjusted solution
RxNorm normalized name: PH-284
DrugBank: PH-284 (DB05452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pH-adjusted solution of 2% mepivacaine with epinephrine
Trial: 1652265
Drug: Standard commercial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard commercial preparation of 2% mepivacaine with epinephrine
Trial: 28993335
Drug: Efavirenz in
RxNorm normalized name: Product containing efavirenz in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efavirenz in combination with Zidovudine-Lamivudine
Trial: 28993335
Drug: Maraviroc in
RxNorm normalized name: Product containing maraviroc in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maraviroc in combination with Zidovudine-Lamivudine
Trial: 25988766
Drug: Carbohydrate-electrolyte solution
RxNorm normalized name: CARBOHYDRATE/ELECTROLYTES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate-electrolyte solution (CES) 3mL·kg(‐1) body mass of a 6% CES every 20 min during exercise
Trial: 21440749
Drug: Low-dose tacrolimus
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose tacrolimus (TAC; 4-6 ng/mL)
Trial: 21440749
Drug: Sirolimus (SRL;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus (SRL; 6-10 ng/mL)
Trial: 21440749
Drug: Low-dose tacrolimus
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose tacrolimus (TAC)
Trial: 11704395
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg eniporide
Trial: 11704395
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg eniporide
Trial: 11704395
Drug: Overall eniporide
RxNorm normalized name: Teniposide
DrugBank: Teniposide (DB00444)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Overall eniporide treatment
Trial: 7191310
Drug: Acemetacin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acemetacin (3 x 30 mg/d)
Trial: 7191310
Drug: Indometacin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indometacin (3 x 50 mg/d)
Trial: 31841699
Drug: BGF MDI
RxNorm normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGF MDI 320/18/9.6 μg
Trial: 27749321
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg/day vs 20 mg/day
Trial: 27749321
Drug: Atorvastatin administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin administration
Trial: 26407654
Drug: Simvastatin 20mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20mg/day (added to both treatments)
Trial: 22288485
Drug: FMUD+AM (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FMUD+AM (375 mg amoxicillin plus 250 mg metronidazole for 7 days)
Trial: 9421099
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg itraconazole orally once a day for 5 days
Trial: 3433371
Drug: Radiotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy plus weekly low-dose cisplatin
Trial: 22986144
Drug: nab-paclitaxel (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nab-paclitaxel (125 mg/m² IV over 30 minutes on days 1, 8, and 15 of each 28-day cycle)
Trial: 26899862
Drug: Intravenous dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous dexamethasone (8 mg)
Trial: 18516888
Drug: Spinal anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anesthesia with 1% hyperbaric lidocaine 1 ml (10 mg) (group L)
Trial: 18516888
Drug: Propofol general
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol general anesthesia (1.0 mg x kg(‐1) injected at 180 mg x kg(‐1) x hr(‐1) followed by continuous infusion at 8 mg x kg(‐1) x hr(‐1) (group P)
Trial: 18516888
Drug: Spinal anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anesthesia with 1% hyperbaric lidocaine (group L)
Trial: 11790169
Drug: Itraconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole (200 mg, twice daily for 6 months)
Trial: 10086433
Drug: Cognitive-behavior therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavior therapy (stimulus control, sleep restriction, sleep hygiene, and cognitive therapy)
Trial: 10086433
Drug: Pharmacotherapy (temazepam)
RxNorm normalized name: Temazepam
DrugBank: Temazepam acetate (DB14671)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy (temazepam)
Trial: 10086433
Drug: Combined behavioral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined behavioral and pharmacological therapy
Trial: 1922223
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 mg slow-release preparation every 8 hours)
Trial: 30300047
Drug: 3 mg·kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg·kg‐1 caffeine
Trial: 30300047
Drug: 1 or
RxNorm normalized name: G-1 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 or 2 mg·kg‐1 caffeine
Trial: 25131925
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment by general practitioner (GP)
Trial: 12324292
Drug: Threonine intake
RxNorm normalized name: Threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Threonine intake of 7 mg x kg(‐1) x d(‐1)
Trial: 12324292
Drug: Threonine intake
RxNorm normalized name: Threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Threonine intake of 11 mg x kg(‐1) x d(‐1)
Trial: 12324292
Drug: Threonine intake
RxNorm normalized name: Threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Threonine intake of 15 mg x kg(‐1) x d(‐1)
Trial: 12324292
Drug: Threonine intake
RxNorm normalized name: Threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Threonine intake of 19 mg x kg(‐1) x d(‐1)
Trial: 12324292
Drug: Threonine intake
RxNorm normalized name: Threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Threonine intake of 22 mg x kg(‐1) x d(‐1)
Trial: 12324292
Drug: Threonine intake
RxNorm normalized name: Threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Threonine intake of 27 mg x kg(‐1) x d(‐1)
Trial: 10756363
Drug: Aprotinin (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (high dose)
Trial: 12539003
Drug: Aprotinin (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (low dose)
Trial: 6991534
Drug: Codeine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codeine (30 mg)
Trial: 883811
Drug: Trimethoprim-sulfamethoxazole (TMP-SMZ)
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMZ) 960 mg TMP and 4800 mg SMZ
Trial: 29951886
Drug: Metoprolol (47.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (47.5 mg once daily)
Trial: 27802097
Drug: Oral oxandrolone
RxNorm normalized name: Oxandrolone
DrugBank: Oxandrolone (DB00621)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral oxandrolone (Ox) 0.06 mg/kg/d for 2 years
Trial: 27802097
Drug: Oral oxandrolone
RxNorm normalized name: Oxandrolone
DrugBank: Oxandrolone (DB00621)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral oxandrolone (Ox)
Trial: 26246443
Drug: Pharmacological modulation
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmacological modulation using selective antagonists for µ‐opioid, dopamine D3 receptor (DRD3), and neurokinin 1 (NK1) receptors (naltrexone, GSK598809, vofopitant/aprepitant) in a placebo-controlled, randomised, crossover design.
Trial: 16554448
Drug: Methylprednisolone 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 0.6 mg/kg ideal body weight
Trial: 12929058
Drug: Ultrathin oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrathin oral (UO) EGD
Trial: 9379783
Drug: Dotarizine 50
RxNorm normalized name: Dotarizine
DrugBank: Dotarizine (DB06446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dotarizine 50 mg (single dose)
Trial: 9379783
Drug: Dotarizine 100
RxNorm normalized name: Dotarizine
DrugBank: Dotarizine (DB06446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dotarizine 100 mg (single dose)
Trial: 9379783
Drug: Dotarizine 200
RxNorm normalized name: Dotarizine
DrugBank: Dotarizine (DB06446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dotarizine 200 mg (single dose)
Trial: 9379783
Drug: Dotarizine 50
RxNorm normalized name: Dotarizine
DrugBank: Dotarizine (DB06446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dotarizine 50 mg (twice daily for 14 days)
Trial: 1588379
Drug: AG plus
RxNorm normalized name: Alamag Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG plus HC (250 mg AG twice a day, 20 mg HC twice a day)
Trial: 1588379
Drug: AG (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG (250 mg AG twice a day)
Trial: 3838405
Drug: Molsidomine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molsidomine (4 mg, sublingually administered)
Trial: 3838405
Drug: Placebo (sublingually
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sublingually administered)
Trial: 30658621
Drug: Group Acceptance
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Acceptance and Commitment Therapy (ACT) intervention delivered over 7 weeks
Trial: 22730105
Drug: Olanzapine monotherapy
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine monotherapy (flexible-dose for 8 weeks)
Trial: 10483607
Drug: 20 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/m2 calcium folinate
Trial: 10483607
Drug: 100 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/m2 calcium folinate
Trial: 10483607
Drug: 650 mg/m2/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 650 mg/m2/d fluorouracil
Trial: 8724043
Drug: Liposomal daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal daunorubicin 40 mg/m2 every 2 weeks for 12 weeks
Trial: 1929343
Drug: Single-dose amoxicillin-clavulanate
RxNorm normalized name: amoxicillin / clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose amoxicillin-clavulanate combination
Trial: 1929343
Drug: 3-day regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-day regimen of amoxicillin-clavulanate
Trial: 30746581
Drug: Yisaipu® tapering
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yisaipu® tapering (50 mg every other week from week 13 to week 24)
Trial: 30746581
Drug: Full-dose therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose therapy (50 mg/week for the entire study duration)
Trial: 28371248
Drug: Targeted group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted group administered antibiotics based on bile culture results
Trial: 28371248
Drug: Standard group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard group administered cefmetazole
Trial: 26410119
Drug: Virtual reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality exposure therapy (VRET) with social interactions; two exposure sessions
Trial: 15256675
Drug: ACE inhibitor
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor therapy (perindopril, 4 mg daily)
Trial: 11778855
Drug: 10% carbamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% carbamide peroxide whitening solution
Trial: 9402352
Drug: Ranitidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (300 mg q.d. for 6 weeks)
Trial: 9402352
Drug: Ranitidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (300 mg q.d. for 6 weeks) with amoxicillin (500 mg t.i.d.) and metronidazole (500 mg b.i.d.) for the first 12 days
Trial: 9402352
Drug: Colloidal bismuth
RxNorm normalized name: Colloidal bismuth subcitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloidal bismuth subcitrate (120 mg q.i.d. for 6 weeks) with amoxicillin and metronidazole (at same dosages as in group B)
Trial: 9402352
Drug: Ranitidine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine with amoxicillin and metronidazole (group B)
Trial: 9402352
Drug: Colloidal bismuth
RxNorm normalized name: Colloidal bismuth subcitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloidal bismuth subcitrate with amoxicillin and metronidazole (group C)
Trial: 3036903
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg DEX, iv, 45-60 min before sternotomy, enflurane anesthesia
Trial: 31728664
Drug: Drospirenone 4
RxNorm normalized name: drospirenone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drospirenone 4 mg (DRSP)
Trial: 31728664
Drug: Desogestrel 0.075
RxNorm normalized name: desogestrel 0.075 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desogestrel 0.075 mg (DSG)
Trial: 9715220
Drug: Availability of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Availability of intravenous catheters
Trial: 7912442
Drug: Both light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both light treatment conditions
Trial: 2660552
Drug: Sucralfate 2
RxNorm normalized name: sucralfate 200 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate 2 g twice daily
Trial: 24899597
Drug: 7.5% CO2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5% CO2 inhalation
Trial: 22733833
Drug: Dabigatran (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran (150 mg twice a day, switching to 110 mg twice a day at age 80)
Trial: 16822563
Drug: Nebivolol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol (5 mg daily for 6 months)
Trial: 16822563
Drug: Metoprolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (100 mg daily for 6 months)
Trial: 15164111
Drug: Cow's milk
RxNorm normalized name: Cow's milk
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cow's milk consumption >500 g/day